New antibiotic combo shows promise against superbug infections

NCT ID NCT03510351

Completed Disease control Sponsor: Temple University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 200 adults with multidrug-resistant Pseudomonas infections who were treated with the antibiotic combination ceftolozane-tazobactam. Researchers tracked how many patients survived at 30 days and while in the hospital, and whether follow-up cultures showed the infection was cleared. The goal was to see if this drug works against these tough-to-treat bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftolozane-tazobactam
What this could lead to: If successful, this could confirm ceftolozane-tazobactam as a reliable treatment for hard-to-treat Pseudomonas infections, potentially saving lives.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. The bacteria may still develop resistance, and individual patient outcomes vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSEUDOMONAS AERUGINOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSEUDOMONAS AERUGINOSA PSEUDOMONAS INFECTIONS

Contacts and locations

Locations

Temple University, School of Pharmacy

Philadelphia, Pennsylvania, 19140, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.